Comorbilidad del trastorno del espectro autista y la epilepsia en edades pediátricas

Introducción: La comorbilidad entre la epilepsia y el trastorno del espectro autista alcanza un alto porcentaje en pacientes pediátricos. Objetivo: Caracterizar la comorbilidad del trastorno del espectro autista y la epilepsia en pacientes pediátricos. Métodos: Estudio observacional, descriptivo, de corte transversal, en una población de 23 sujetos. Resultados: Predominaron los pacientes del sexo femenino (n = 14; 60,9 %). La totalidad de los individuos acudió a la primera consulta, fue diagnosticado con trastorno del espectro autista y sufrió la primera crisis epiléptica con 9 años de edad o menos. El 78,3 % (n= 18) nació entre las 38 y 42 semanas de gestación, y el 65,2 % (n= 15) fue diagnosticado con trastorno de déficit intelectual. Lo más común fue la inexistencia de factores de riesgo (n= 14; 60,9 %). Las crisis epilépticas generalizadas fueron las más frecuentes (n= 12; 52,17 %). Predominaron los individuos con trastorno del espectro autista congénito (n= 16; 69,57 %) e idiopático (n= 8; 64,78) En el 56,5 % (n= 13), la primera crisis epiléptica antecedió al diagnóstico del trastorno del espectro autista. Conclusiones: En la población estudiada, la comorbilidad entre epilepsia y trastorno del espectro autista se produce fundamentalmente en el sexo femenino, antes de la primera década de la vida, con coexistencia de un trastorno de déficit intelectual y la ausencia de factores de riesgo, en el contexto de crisis epilépticas generalizadas y un trastorno del espectro autista congénito, profundo, idiopático y con diagnóstico posterior al de la epilepsia.

Introduction: The comorbidity between epilepsy and autism spectrum disorder reaches a high percentage of pediatric patients. Objective: To characterize the comorbidity of autism spectrum disorder and epilepsy in pediatric patients. Methods: Observational, descriptive, cross-sectional study in a population of 23 subjects. Results: Female patients predominated (n= 14; 60.9%). All of the individuals attended the first consultation, were diagnosed with autism spectrum disorder and suffered the first epileptic seizure at 9 years or younger. 78.3% (n= 18) were born between 38 and 42 weeks of gestation, and 65.2% (n= 15) were diagnosed with intellectual disability disorder. The absence of risk factors was the most common characteristic (n= 14; 60.9 %). Generalized seizures were the most frequent (n= 12; 52.17%). Individuals with congenital (n= 16; 69.57%) and idiopathic (n= 8, 64.78) autism spectrum disorder predominated. In 56.5% (n= 13), the first epileptic seizure preceded the diagnosis of autism spectrum disorder. Conclusions: In the population studied, the comorbidity between epilepsy and autism spectrum disorder occurs mainly in females, before the first decade of life, with coexistence of an intellectual disability disorder and the absence of risk factors, in the context of generalized epileptic seizures and a congenital, profound, idiopathic autism spectrum disorder, and diagnosed after epilepsy.

Clinical Phenotypes and Mortality Biomarkers: A Study Focused on COVID-19 Patients with Neurological Diseases in Intensive Care Units.

Purpose: To identify clinical phenotypes and biomarkers for best mortality prediction considering age, symptoms and comorbidities in COVID-19 patients with chronic neurological diseases in intensive care units (ICUs). Subjects and Methods: Data included 1252 COVID-19 patients admitted to ICUs in Cuba between January and August 2021. A k-means algorithm based on unsupervised learning was used to identify clinical patterns related to symptoms, comorbidities and age. The Stable Sparse Classifiers procedure (SSC) was employed for predicting mortality. The classification performance was assessed using the area under the receiver operating curve (AUC). Results: Six phenotypes using a modified v-fold cross validation for the k-means algorithm were identified: phenotype class 1, mean age 72.3 years (ys)-hypertension and coronary artery disease, alongside typical COVID-19 symptoms; class 2, mean age 63 ys-asthma, cough and fever; class 3, mean age 74.5 ys-hypertension, diabetes and cough; class 4, mean age 67.8 ys-hypertension and no symptoms; class 5, mean age 53 ys-cough and no comorbidities; class 6, mean age 60 ys-without symptoms or comorbidities. The chronic neurological disease (CND) percentage was distributed in the six phenotypes, predominantly in phenotypes of classes 3 (24.72%) and 4 (35,39%); χ² (5) 11.0129 p = 0.051134. The cerebrovascular disease was concentrated in classes 3 and 4; χ² (5) = 36.63, p = 0.000001. The mortality rate totaled 325 (25.79%), of which 56 (17.23%) had chronic neurological diseases. The highest in-hospital mortality rates were found in phenotypes 1 (37.22%) and 3 (33.98%). The SSC revealed that a neurological symptom (ageusia), together with two neurological diseases (cerebrovascular disease and Parkinson's disease), and in addition to ICU days, age and specific symptoms (fever, cough, dyspnea and chilliness) as well as particular comorbidities (hypertension, diabetes and asthma) indicated the best prediction performance (AUC = 0.67). Conclusions: The identification of clinical phenotypes and mortality biomarkers using practical variables and robust statistical methodologies make several noteworthy contributions to basic and experimental investigations for distinguishing the COVID-19 clinical spectrum and predicting mortality.

Grado de riesgo biológico al manipular toxina botulínica como medicamento / Degree of Biohazard When Handling Botulinum Toxin as A Medication

Introducción: El uso de la toxina como medicamento constituye un riesgo biológico, debido a la presencia de la toxina, así como al uso indebido que se le puede dar. Objetivo: Evaluar el grado de riesgo biológico al manipular toxina botulínica como medicamento. Métodos: Estudio descriptivo transversal en el Centro Internacional de Restauración Neurológica, La Habana, Cuba, en 2017. Se aplicó una lista de chequeo de riesgo biológico a 6 profesionales del área de tratamiento de toxina botulínica. El resultado integrado de la lista de chequeo se analizó a través del método semicuantitativo "ERBIO". Resultados: La probabilidad se catalogó de "media", el cumplimiento de medidas de contención como "aceptable" y la exposición se consideró como "muy frecuente". Conclusiones: Se constató un grado de riesgo biológico "tolerable" al manipular la toxina botulínica como medicamento en el Centro Internacional de Restauración Neurológica. Esto implica que se deben considerar mejoras que no supongan una carga económica importante, que requerirán de comprobaciones periódicas para asegurar el mantenimiento de la eficacia de las medidas de control establecidas(AU)

Introduction: The use of the toxin as a medication constitutes a biological risk, due to the presence of the toxin, as well as the potential improper use. Objective: To evaluate the degree of biological risk when Handling botulinum toxin as a medication. Methods: A cross-sectional descriptive study was carried out at the International Center for Neurological Restoration, Havana, Cuba, in 2017. A biological risk checklist was applied to six professionals from the botulinum toxin treatment area. The integrated result of the checklist was analyzed through ERBIO semi-quantitative method. Results: The probability was classified as medium. Compliance with containment measures was assessed as acceptable and the exposure was considered as very frequent. Conclusions: A tolerable degree of biological risk was found when manipulating botulinum toxin as a medication at the International Center for Neurological Restoration. This implies that improvements should be considered not to imply a significant economic burden, which will require periodic checks to ensure the maintenance of the effectiveness of the established control measures(AU)

Funcionamiento familiar y esfuerzo percibido por el cuidador primario de niños con enfermedades neurológicas / Family functioning and perceived effort by the primary caregiver of children with neurological diseases

RESUMEN Fundamento: Las investigaciones que intentan relacionar el funcionamiento familiar y el esfuerzo percibido por el cuidador primario de niños con enfermedades neurológicas, documentan resultados divergentes e insuficientes. Objetivo: identificar la relación entre el funcionamiento familiar y el esfuerzo percibido por el cuidador primario de niños con enfermedades neurológicas. Métodos: estudio de serie de casos, realizado en el Servicio de Neuropsicología, del Centro Internacional de Restauración Neurológica, en el segundo semestre de 2018. Los participantes fueron 12 cuidadores de niños entre uno y seis años de edad. Se aplicó entrevista estructurada, índice de esfuerzo del cuidador, escala de funcionamiento familiar/FF-SIL, inventario de características familiares de riesgo y análisis documental. Se utilizó estadística descriptiva, comparación de medias y correlación de Spearman. Resultados: el 92 % de los cuidadores no había recibido información de cómo cuidarse, ni de cómo cuidar a su hijo. El índice de esfuerzo del cuidador manifestó iguales proporciones para los niveles elevado y bajo (50 % respectivamente). Se observó relación entre edad de los cuidadores y edad de desarrollo de los niños y el funcionamiento familiar (r=0,71, r=0,67); así como entre el índice de esfuerzo del cuidador y el inventario de riesgos familiares (r=0,72). Conclusión: Los cuidadores primarios estudiados carecen de información de autocuidado y del cuidado de su hijo; una criticidad elevada y un índice de esfuerzo del cuidador heterogéneo, lo cual se relaciona con los riesgos familiares. La edad de los cuidadores y la edad de desarrollo de los niños influyen en el funcionamiento familiar.

ABSTRACT Foundation: Research that attempts to relate family functioning and the effort perceived by the primary caregiver of children with neurological diseases, documents divergent and insufficient results. Objective: to identify the relationship between family functioning and the effort perceived by the primary caregiver of children with neurological diseases. Methods: case series study, conducted at the Neuropsychology Service, of the International Center for Neurological Restoration, in the second half of 2018. The participants were 12 children caregivers between one and six years old. Structured interview, caregiver effort index, family functioning scale / FF-SIL, inventory of family risk characteristics and documentary analysis were applied. Descriptive statistics, comparison of means and Spearman correlation were used. Results: 92% of caregivers had not received information on how to take care of themselves, or how to care for their child. The caregiver effort index showed equal proportions for the high and low levels (50% respectively). The relationship between caregivers´ age, children´s development age and family functioning was observed (r = 0.71, r = 0.67); as well as between the caregiver's effort index and the family risk inventory (r = 0.72). Conclusion: The primary caregivers studied lack self-care information and care of their child; a high criticality and an effort index of the heterogeneous caregiver, which is related to family risks. The age of caregivers and the age of children´s development influence family functioning.

Uso de toxina botulínica tipo A en pacientes con Espasmo Hemifacial en Cuba / Botulinum toxin A in hemifacial spasm in Cuba

Resumen Objetivo: Evaluar los resultados terapéuticos de la aplicación de la toxina botulínica tipo A en pacientes con espasmo hemifacial atendidos en una consulta de Neurología de trastornos de movimiento en Cuba. Métodos: Se determinaron variables temporales: latencia, duración del efecto máximo y desaparición del efecto terapéutico de la toxina botulínica a 35 pacientes con espasmo hemifacial. Fueron evaluados el deterioro funcional, gravedad, frecuencia y efectos adversos. Resultados: Hubo predominio de mujeres (88,6%) con esta enfermedad. El tiempo de latencia más frecuente resultó ser 48 hs, la duración del efecto máximo hasta los 60 días y la desaparición del efecto terapéutico hasta 3 meses. El deterioro funcional mejoró entre la consulta inicial y los 15 meses de evolución, independientemente del tiempo de presentación de los síntomas y causa del espasmo hemifacial. También, la gravedad y frecuencia mejoraron. Las dosis de toxina botulinica aunmentó significativamente durante el seguimiento de los pacientes. Solo se observaron pacientes con debilidad muscular facial y ptosis parpebral. Conclusiones: Debido al favorable comportamiento de las variables temporales, la mejoría del deterioro funcional evolutivo, y los pocos efectos adversos observados se pudiera sugerir que las dosis de toxina botulínica en el tratamiento del espasmo hemifacial parecen ser eficaces y seguras.

Abstract Objective: To evaluate botulinum toxin A therapy in patients with hemifacial spasm attended in a Neurology Service in Cuba. Patients and methods: 35 patients with hemifacial spasm were treated with botulinum toxin A during 15 months. Some parameters of botulinum toxin were collected including doses, latency, maximum duration and total duration of improvement. Clinical data were determined, such as functional status, gravity, frequency and adverse events. Results: There was a high percentage of female with hemifacial spasm. Most patients showed a latency of 48 hs, maximum duration until 60 days and total duration of improvement of 3 months. Functional status decreased through time, independently of hemifacial spasm onset and its origin. Parameters related to functional status, as gravity and frequency also diminished significantly their categories. Botulinum toxin doses were statistically increased over this treatment, independently of any patient conditions. Only eight patients showed adverse events (facial muscle weakness and ptosis). Conclusions: Recovery of functional status, and low rate of adverse events observed during botulinum toxin treatment might suggest that this therapy seems to be effective and low-risk under our conditions.

Peripheral Inflammatory Markers Contributing to Comorbidities in Autism.

This study evaluates the contribution of peripheral biomarkers to comorbidities and clinical findings in autism. Seventeen autistic children and age-matched typically developing (AMTD), between three to nine years old were evaluated. The diagnostic followed the Diagnostic and Statistical Manual of Mental Disorders 4th Edition (DMS-IV) and the Childhood Autism Rating Scale (CARS) was applied to classify the severity. Cytokine profile was evaluated in plasma using a sandwich type ELISA. Paraclinical events included electroencephalography (EEG) record. Statistical analysis was done to explore significant differences in cytokine profile between autism and AMTD groups and respect clinical and paraclinical parameters. Significant differences were found to IL-1ß, IL-6, IL-17, IL-12p40, and IL-12p70 cytokines in individuals with autism compared with AMTD (p < 0.05). All autistic patients showed interictalepileptiform activity at EEG, however, only 37.5% suffered epilepsy. There was not a regional focalization of the abnormalities that were detectable with EEG in autistic patients with history of epilepsy. A higher IL-6 level was observed in patients without history of epilepsy with interictalepileptiform activity in the frontal brain region, p < 0.05. In conclusion, peripheral inflammatory markers might be useful as potential biomarkers to predict comorbidities in autism as well as reinforce and aid informed decision-making related to EEG findings in children with Autism spectrum disorders (ASD).

Sindrome de Shy-drager. A proposito de dos casos / The Shy-Drager syndrome. In connecttion with two cases

Presentamos dos pacientes masculinos, en la sexta decada de la vida, cion un cuadro clinico muy manifiesto del Sindrome Shy-Drager (SSD). El sintoma cardinal de estos enfermos esta dado por caidas frecuentes, por hipotension arterial ortostatica, con inconciencia, sin respuesta vegetativa simpatica (sin frialdad ni taquicardia y con anhidrosis). De forma sumaria el resto del cuadro neurologico estaba expresado por parkinsonismo, impotencia sexual, incontinencia esfinteriana, vesical, disfuncion, cerebelosa, hemiparesia, atrofias musculares, etc. Uno de los pacientes fue autopsiado y se revelo extenso proceso degenerativo cronico neuronal en el sistema nervioso central, asi como en el periferico, donde incluye el sistema autonomico y atrofia muscular neurogena. El estridor laringeo de uno de los enfermos durante el sueno, lo atribuimos a la imposibilidad de la abduccion de las cuerdas vocales en la inspiracion, por atrofia del musculo criacoritenoideo posterior. La respuesta en el caso dos, el tratmiento con indometacina, esteroides y vendaje elastico en los miembros inferiores, fue satisfactoria